Biogen Stock Forecast for 2023 - 2025 - 2030

Updated on 03/29/2024

Stock Rating
10
Price Target
$297.00
Consensus
Outperform
Upside
29.09%
Analysts
13
Stock Rating
10
Upside
29.09%
Analysts
13
Price Target
$297.00

Biogen Stock Forecast and Price Target

Given the average yearlong price target of $297.00 provided by thridteen prominent analysts over the past few months, there is a potential upside of approximately 29.09% from the last closing price in March, 2024 for Biogen's stock if it is reached. This estimation is based on a high estimate of $400.00 and a low estimate of $230.00. If you're interested in investing in this company, why not also look at its competitors to see how they are doing?

$297.00

29.09% Upside

Outperform
Outperform

Biogen Fair Value Forecast for 2023 - 2025 - 2030

In the last four years, Biogen's Price has decreased from $423.95 to $0.00 – a 100.00% drop. In the next year, analysts predict that Fair Value will reach $211.60 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.

2024 Fair Value Forecast
$211.60
2025 Fair Value Forecast
$223.92
2026 Fair Value Forecast
$245.18
2027 Fair Value Forecast
$248.71
2028 Fair Value Forecast
$264.18
2029 Fair Value Forecast
$288.71
2030 Fair Value Forecast
$304.69
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LLY Stock Forecast Eli Lilly and Outperform 16
$734.37 Buy/Sell $636.99 10.71%
NOVO B Stock Forecast Novo Nordisk A/S Outperform 12
kr895.10 Buy/Sell kr696.07 6.13%
JNJ Stock Forecast Johnson & Johnson Outperform 9
$161.23 Buy/Sell $174.55 5.44%
ABBV Stock Forecast AbbVie Outperform 9
$179.63 Buy/Sell $178.42 0.21%
MRK Stock Forecast Merck Outperform 2
$122.77 Buy/Sell $130.51 9.96%

Biogen Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Biogen's Revenue has decreased from $13.44B to $9.84B – a 26.84% drop. For the following year, the 26 analysts predict that Biogen's Revenue will drop by 3.82%, reaching $9.46B. For the next seven years, the forecast is for Revenue to grow by 8.44%.

2024 Rev Forecast
$9.46B
2025 Rev Forecast
$9.85B
2026 Rev Forecast
$10.20B
2027 Rev Forecast
$10.15B
2028 Rev Forecast
$10.26B
2029 Rev Forecast
$10.54B
2030 Rev Forecast
$10.67B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ROG Stock Forecast Roche Holding Hold 16
CHF242.00 Buy/Sell CHF307.83 11.57%
AZN Stock Forecast AstraZeneca PLC Outperform 17
£104.50 Buy/Sell £165.99 53.79%
NOVN Stock Forecast Novartis Outperform 10
CHF88.80 Buy/Sell CHF105.00 23.95%

Biogen Dividend per Share Forecast for 2023 - 2025 - 2030

2024 DPS Forecast
$0.00
2025 DPS Forecast
$0.00
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.00
2028 DPS Forecast
$0.00
2029 DPS Forecast
$0.00
2030 DPS Forecast
$0.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
DHR Stock Forecast Danaher Outperform 10
$252.80 Buy/Sell $260.33 2.85%
PFE Stock Forecast Pfizer Outperform 2
$28.37 Buy/Sell $32.87 10.82%
AMGN Stock Forecast Amgen Outperform 4
$275.36 Buy/Sell $303.65 14.40%

Biogen Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
$2.90B
2025 FCF Forecast
$2.88B
2026 FCF Forecast
$3.02B
2027 FCF Forecast
$2.99B
2028 FCF Forecast
$3.00B
2029 FCF Forecast
$3.01B
2030 FCF Forecast
$3.11B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
SAN Stock Forecast Sanofi Outperform 16
88.32€ Buy/Sell 102.80€ 21.15%
MDT Stock Forecast Medtronic Outperform 11
$85.50 Buy/Sell $92.47 11.11%
BMY Stock Forecast Bristol-Myers Squibb Hold 2
$54.36 Buy/Sell $58.15 1.18%

Biogen EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, Biogen has seen a decline in its EBITDA, from $5.11B to $2.38B – a 53.51% decrease. In the next year, analysts expect EBITDA to reach $3.83B – an increase of 61.13%. For the next seven years, the forecast is for EBITDA to grow by 53.22%.

2024 EBITDA Forecast
$3.83B
2025 EBITDA Forecast
$4.13B
2026 EBITDA Forecast
$4.32B
2027 EBITDA Forecast
$3.51B
2028 EBITDA Forecast
$3.48B
2029 EBITDA Forecast
$3.48B
2030 EBITDA Forecast
$3.64B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
VRTX Stock Forecast Vertex Pharmaceuticals Inc Outperform 12
$414.47 Buy/Sell $457.59 8.57%
REGN Stock Forecast Regeneron Pharmaceuticals Outperform 2
$964.44 Buy/Sell $961.26 8.87%
GILD Stock Forecast Gilead Sciences Inc Outperform 11
$75.32 Buy/Sell $87.82 10.20%

Biogen EBIT Forecast for 2023 - 2025 - 2030

In the last three years, Biogen's EBIT has decreased by 59.57%, from $4.66B to $1.88B. The next year looks promising for Biogen, with analysts predicting EBIT of $2.94B – an increase of 56.08%. Over the next seven years, experts anticipate that Biogen's EBIT will grow at a rate of 71.28%.

2024 EBIT Forecast
$2.94B
2025 EBIT Forecast
$3.16B
2026 EBIT Forecast
$3.34B
2027 EBIT Forecast
$3.13B
2028 EBIT Forecast
$3.12B
2029 EBIT Forecast
$3.20B
2030 EBIT Forecast
$3.22B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CSL Stock Forecast CSL Outperform 12
$281.20 Buy/Sell $205.51 -27.94%
GSK Stock Forecast GSK Outperform 12
£16.75 Buy/Sell £17.30 11.04%
ZTS Stock Forecast Zoetis Outperform 18
$183.49 Buy/Sell $220.47 20.72%

Biogen EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last four years, Biogen's EPS has decreased from $33.70 to $0.00 – a 100.00% drop. In the next year, analysts predict that EPS will reach $16.82 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.

2024 EPS Forecast
$16.82
2025 EPS Forecast
$17.80
2026 EPS Forecast
$19.49
2027 EPS Forecast
$19.77
2028 EPS Forecast
$21.00
2029 EPS Forecast
$22.95
2030 EPS Forecast
$24.22
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
MRK Stock Forecast Merck KGaA Outperform 18
156.75€ Buy/Sell 190.06€ 9.73%
4502 Stock Forecast Takeda Pharmaceutical Company Outperform 5
¥4.31k Buy/Sell ¥4.74k 6.63%
MRNA Stock Forecast Moderna Outperform 16
$111.98 Buy/Sell $135.42 11.09%